Continuing filgotinib treatment for juvenile arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study lets young people who benefited from filgotinib (a medication that reduces inflammation) in a previous trial continue taking it to see if it stays safe and effective over a longer period. It's designed for patients ages 8–17 who did well on this medicine before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed a previous filgotinib trial and saw improvement in your arthritis symptoms
- You are between 8 and 17 years old
- You are willing to follow the study plan and visit the clinic as scheduled
- If you are a girl who could become pregnant, you agree to use birth control during the study
- You do not have an active serious infection or other condition that would make the medicine unsafe for you
- You are not allergic to any ingredient in filgotinib
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the use of a medication called tofacitinib in children and teenagers with juvenile idiopathic arthritis (JIA), a type of arthritis that starts in childhood. The goal is to see if the drug helps reduce joint pain and inflammation.
This study looks at when it may be safe to stop or reduce arthritis medications in children whose juvenile idiopathic arthritis has been inactive for at least 6 months. The goal is to find the best time to stop treatment to avoid side effects while preventing flare-ups.
This study compares stopping JAK inhibitor treatment versus continuing the same dose for people with ulcerative colitis who are in deep remission. If you are doing well on your current JAK inhibitor, this trial may help you understand if you can safely stop it.
This trial tests filgotinib, a new medication that may help reduce joint swelling and pain in children and teens (ages 8–17) with polyarticular juvenile idiopathic arthritis—a type of childhood arthritis affecting multiple joints. You're eligible if your current arthritis medicines haven't worked well enough.
This trial tests if filgotinib, a pill for adults with ulcerative colitis, works in children and teenagers. It may help those whose current treatments are not working well enough or cause side effects.
This Phase 4 study compares two treatment options for rheumatoid arthritis (RA): filgotinib or a TNF inhibitor (TNFi). It is designed for adults whose current “standard” RA tablets have not worked well or were not tolerated, to see which approach improves RA control.
Hear when a new Juvenile Idiopathic Arthritis (JIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.